Cerus (CERS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Executive summary
Annual meeting scheduled for June 2, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of two directors, William M. Greenman and Ann Lucena, to serve until the 2029 annual meeting.
Approval of an amendment and restatement of the 2024 Equity Incentive Plan, increasing authorized shares by 10 million and making additional changes.
Advisory vote on executive compensation for named executive officers.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and plan amendments.
Latest events from Cerus
- Q2 2026 product revenue up 10% to $57.4M, guidance raised, and liquidity improved.CERS
Q2 2026 - All proposals passed, including director elections and plan amendments, with no shareholder questions.CERS
AGM 2026 - Q1 2026 revenue up 23%, product revenue up 24%, and net loss narrowed to $1.6 million.CERS
Q1 2026 - Record revenue growth and global expansion driven by INTERCEPT blood safety technologies.CERS
Corporate presentation - Proxy covers director elections, equity plan expansion, pay, auditor, and governance highlights.CERS
Proxy filing - 2025 revenue rose 16% with narrowing losses and surging INTERCEPT Fibrinogen Complex demand.CERS
Q4 2025 - Q2 revenue up 16%, net loss narrowed, and 2024 guidance raised on strong North American growth.CERS
Q2 2024 - Q3 2024 product revenue up 16%, net loss narrowed, and full-year guidance raised.CERS
Q3 2024 - BARDA awards up to $248M for U.S. program; Europe plans new submission after CE Mark setback.CERS
Study Update